Extractable thesis: "In ex-vivo human gut models, TRI-01 induces its lead target species Agathobaculum butyriciproducens — a neuroprotective keystone species — by +45-fold on its own and up to +96-fold in combination, alongside increases in three further keystone species."
What's shown today
Ex-vivo induction of the target consortium
In ex-vivo human gut models (donor-stool fermentation), TRI-01 selectively increases its four target keystone species:
| Species | Fold-change (ex-vivo) |
|---|---|
| Agathobaculum butyriciproducens | +45-fold standalone · +96-fold in combination |
| Coprococcus catus | +15-fold standalone |
| Anaerostipes hadrus | +9-fold standalone |
| Faecalibacillus intestinalis | +9-fold standalone |
Ex-vivo human gut models are the standard system for establishing that an ingredient shifts named species. This is the mechanistic foundation the human programme is built on.
Published science on the lead species
The target species are not arbitrary. Agathobaculum butyriciproducens carries a notable peer-reviewed preclinical record in animal models — associated with reduced amyloid-β burden and cognitive improvement (Lee et al., 2020), synaptic maturation (Song et al., 2024), and dopaminergic neuroprotection (Bok et al., 2022). This is peer-reviewed work on the species themselves, and it is why these four were chosen as targets.
What's planned
Our evidence deepens in a deliberate sequence: controlled human work on TRI-01 beginning with gut-health endpoints, and a parallel track for TRI-04 toward its metabolic-health claim path. Each stage is built to convert mechanism into substantiation a brand can put on pack.
Designs, endpoints and timing are shared with partners under confidentiality.
A cognitive endpoint is the long-horizon goal for TRI-01.
A third-party signal
Beyond our own data, the European Patent Office, in its Search Opinion on our priority application, acknowledged the plausibility of the cognitive rationale behind the lead mechanism. The exact wording — with its hedges preserved — is on the IP page.
The claim ladder
Evidence and claims move together. At launch, the data supports gut-health structure-function claims. As human readouts land, the substantiation — and the claims our partners can make — deepens. We price and position to that ladder.
How it works → Quality & manufacturing →
FAQ
- What evidence exists today? Ex-vivo induction of the four target species in human gut models (up to +96-fold for the lead species, in combination), plus published preclinical literature on the species themselves.
- What stage is the evidence at? Ex-vivo induction of the four target species in human gut models, plus published peer-reviewed literature on the species. The human programme follows.
- What can a brand claim today? Gut-health structure-function claims at launch, with the ceiling rising as human readouts land.
- What did the EPO say? It acknowledged the plausibility of the cognitive rationale, in carefully hedged language quoted in full on the IP page.
- What is an ex-vivo human gut model? A fermentation system seeded with human donor stool, used to measure how a compound changes the microbial community. It is the standard way to test whether an ingredient shifts named species before a human trial.
- At what dose was the effect measured? In ex-vivo human gut models at the intake the product is designed for. Dose detail for each active sits on its own product page.